Abstract:The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A1 are produced by different Streptomyces strains. They are potent inhibitors of bacterial gyrase and topoisomerase IV, and novobiocin has been licensed as antibiotic for clinical use (Albamycin®). They also have potential applications in oncology. The biosynthetic gene clusters of all three antibiotics have been cloned and sequenced, and the function of nearly all genes contained therein has been elucidated. Rapid and versatile methods have been developed for the heterologous expression of these biosynthetic gene clusters, and in Streptomyces coelicolor M512 as heterologous host these antibiotics were produced in yields comparable to those in the natural producer strains. λ RED-mediated homologous recombination was used for genetic modification of the gene clusters in Escherichia coli. The phage φC31 attachment site and integrase functions were introduced into the cosmid backbones and employed for stable integration of the clusters into the genome of the heterologous hosts. Modification of the clusters by single or multiple gene replacements or gene deletions resulted in the formation of numerous new aminocoumarin derivatives, providing an efficient tool for the rational generation of antibiotics with modified structure. Additionally, many new antibiotics were generated by mutasynthesis experiments, i.e. the targeted deletion of genes required for the biosynthesis of a certain structural moiety of the antibiotic, and the replacement of this moiety by structural analogs which were added to the culture broth. The diversity of new structures obtained by this approach could be expanded by further genetic modifications of the gene deletion mutants, especially by expression of heterologous biosynthetic enzymes with appropriate substrate specificity. Keywords: acyl carrier protein, Novobiocin, clorobiocin analogs, genetic manipulations, Streptomyces coelicolor

Metabolic Engineering of Aminocoumarins: Inactivation of the Methyltransferase Gene Clop and Generation of New Clorobiocin Derivatives in a Heterologous Host

In Vitro and in Vivo Production of New Aminocoumarins by A Combined Biochemical, Genetic, and Synthetic Approach

Functional Analysis of Biosynthetic Genes of Aminocoumarins and Production of Hybrid Antibiotics

New Aminocoumarin Antibiotics from Genetically Engineered Streptomyces Strains.

Aminocoumarins: Mutasynthesis, Chemoenzymatic Synthesis, And Metabolic Engineering

Chapter 18 Aminocoumarins

Combinatorial Biosynthesis, Metabolic Engineering and Mutasynthesis for the Generation of New Aminocoumarin Antibiotics

Genetic Engineering of Antibiotic Biosynthesis for the Generation of New Aminocoumarins

New Aminocoumarin Antibiotics Derived from 4-Hydroxycinnamic Acid Are Formed after Heterologous Expression of a Modified Clorobiocin Biosynthetic Gene Cluster

Biosynthesis of Clorobiocin: Investigation of the Transfer and Methylation of the Pyrrolyl-2-carboxyl Moiety

Metabolic engineering of the heterologous production of clorobiocin derivatives and elloramycin in Streptomyces coelicolor M512.

New aminocoumarin antibiotics as gyrase inhibitors.

An Artificial Pathway to 3,4-Dihydroxybenzoic Acid Allows Generation of New Aminocoumarin Antibiotic Recognized by Catechol Transporters of E. coli

Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis.

The Biosynthetic Gene Clusters of Aminocoumarin Antibiotics

Molecular cloning and sequence analysis of the clorobiocin biosynthetic gene cluster: new insights into the biosynthesis of aminocoumarin antibiotics.

Clorobiocin Biosynthesis in Streptomyces: Identification of the Halogenase and Generation of Structural Analogs

Clon6, A Novel Methyltransferase Catalysing the Methylation of the Pyrrole-2-Carboxyl Moiety of Clorobiocin

Novobiocin Biosynthesis: Inactivation of the Putative Regulatory Gene Nove and Heterologous Expression of Genes Involved in Aminocoumarin Ring Formation

Antimicrobial and DNA Gyrase-Inhibitory Activities of Novel Clorobiocin Derivatives Produced by Mutasynthesis.

Assembly and Heterologous Expression of the Coumermycin A1 Gene Cluster and Production of New Derivatives by Genetic Engineering